SCHEMBL1463349

SCHEMBL1463349

COc1ccc(NC(=O)Nc2cccc(C(F)(F)F)c2)c(O)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.66
GSK3B P49841 1/20 0.66
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
HTT P42858 3/20 0.59
LMNA P02545 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
POLB P06746 1/20 0.59
KDR P35968 4/20 0.59
NTRK1 P04629 1/20 0.59
CDK19 Q9BWU1 1/20 0.59
GRIK1 P39086 2/20 0.58
MAPT P10636 5/20 0.58
RAB9A P51151 1/20 0.58
RXFP1 Q9HBX9 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
ALDH1A1 P00352 1/20 0.57
GAA P10253 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
NPC1 O15118 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1462402 0.91 NTRK1 (0.69) GSK3AGSK3BMEN1KMT2AHTT
SCHEMBL6764064 0.89 P2RX1 (0.64) GSK3AGSK3BMEN1KMT2ASMN1; SMN2
SCHEMBL1463485 0.88 AKR1C3 (0.70) GSK3AGSK3BMEN1KMT2AHTT
SCHEMBL6372247 0.88 GSK3A (0.66) GSK3AGSK3BMEN1KMT2AHTT
SCHEMBL6760901 0.86 EPHX2 (0.56) MEN1KMT2AHTTLMNASMN1; SMN2
SCHEMBL1463622 0.86 TRPV1 (0.70) MEN1KMT2AHTTKDRNTRK1
SCHEMBL8370207 0.86 GSK3A (0.66) GSK3AGSK3BMEN1KMT2AHTT
SCHEMBL6922528 0.86 TRPV1 (0.66) GSK3AGSK3BMEN1KMT2AHTT
SCHEMBL6370472 0.85 MAPT (0.72) GSK3AGSK3BMEN1KMT2AHTT
SCHEMBL1464153 0.85 KDR (0.58) MEN1KMT2AHTTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663192-B1 hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS NEUROSEARCH AS (DK) 2008-12-03 EP claimed
US-20070293553-A1 Diphenylurea Derivatives Useful As Potassium Channel Activators NEUROSEARCH A/S (DK) 2007-12-20 US claimed
US-20060281794-A1 Erg channel openers for the treatment of cardiac arrhythmias NEUROSEARCH A/S (DK) 2006-12-14 US claimed
EP-1663192-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS Poseidon Pharmaceuticals A/S (DK) 2006-06-07 EP claimed
WO-2005023237-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS POSEIDON PHARMACEUTICALS A/S (DK) 2005-03-17 WO claimed
WO-2005023238-A1 ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES POSEIDON PHARMACEUTICALS A/S (DK) 2005-03-17 WO claimed
US-20040063742-A1 Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity NEUROSEARCH A/S (DK) 2004-04-01 US claimed
EP-0693053-B1 UREA AND AMIDE DERIVATIVES AND THEIR USE IN THE CONTROL OF CELL MEMBRANE POTASSIUM CHANNELS NEUROSEARCH AS (DK) 1999-01-20 EP claimed
US-5696138-A Urea derivatives and their use NEUROSEARCH A/S (DK) 1997-12-09 US claimed
EP-0693053-A1 UREA AND AMIDE DERIVATIVES AND THEIR USE IN THE CONTROL OF CELL MEMBRANE POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 1996-01-24 EP claimed
WO-1994022807-A1 UREA AND AMIDE DERIVATIVES AND THEIR USE IN THE CONTROL OF CELL MEMBRANE POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 1994-10-13 WO claimed
WO-2024019128-A1 PLANT BIOMASS SACCHARIFYING ENZYME COMPOSITION 花王株式会社 2024-01-25 WO disclosed
EP-3439706-A1 PRODUCT ENABLING THE FORMATION OF A THERAPEUTIC IMPLANT INSIDE THE BODY OF A SUBJECT - ASSOCIATED IMPLANT AND COMPOSITION Gelnesis (FR) 2019-02-13 EP disclosed
CN-106518683-A Method and device for synthesizing triethyl citrate by applying vapor permeation dehydration technique 江苏九天高科技股份有限公司 2017-03-22 CN disclosed
CN-103573431-B VARIABLE VALVE TIMING FOR EGR CONTROL 福特环球技术公司 2017-03-22 CN disclosed
WO-1997045111-A1 PHENYL DERIVATIVES USEFUL AS BLOCKERS OF CHLORIDE CHANNELS NEUROSEARCH A/S (DK) 1997-12-04 WO disclosed
WO-1997034972-A1 FABRIC SOFTENING COMPOUND/COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 1997-09-25 WO disclosed
US-5511547-A Solid state sensors BIOMEDICAL SENSORS, LTD. (GB) 1996-04-30 US disclosed
EP-0693053-A1 UREA AND AMIDE DERIVATIVES AND THEIR USE IN THE CONTROL OF CELL MEMBRANE POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 1996-01-24 EP disclosed
WO-1994022807-A1 UREA AND AMIDE DERIVATIVES AND THEIR USE IN THE CONTROL OF CELL MEMBRANE POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 1994-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281794-A1 Erg channel openers for the treatment of cardiac arrhythmias KCNJ2, KCNN3, KCNE1 GSK3A 4265/4885GSK3B 4433/4885MEN1 2084/4885
US-20070293553-A1 Diphenylurea Derivatives Useful As Potassium Channel Activators KCNJ2, KCNH2, KCNH3 GSK3A 3119/4885GSK3B 3163/4885MEN1 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.